NCT00287287View on ClinicalTrials.gov

REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas

PHASE2CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

July 6, 2010

Study Completion Date

July 6, 2010

Conditions

Thyroid Neoplasms

Interventions

DRUG

Lenalidomide

Initial dose is 25 mg/day dose will be adjusted accordingly as needed. Dose range for the study is 5 to 25 mg/day

Trial Locations (1)

40536

University of Kentucky Markey Cancer Center, Lexington

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

Kenneth Ain

OTHER